Center-Authored Papers

Browse: Authors | Keywords | All Center-Authored Publications
Filter by Division: Basic | Clinical | Human Biology | PHS | VIDD (2010-present) | VIDI (2008-2009)
Filter by Year: 2008 | 2009 | 2010 | 2011 | 2012 | 2013

Filters: Keyword is Prostate-Specific Antigen  [Clear All Filters]
A
Agalliu, I, Suuriniemi M, Prokunina-Olsson L, Johanneson B, Collins FS, Stanford JL, Ostrander EA.  2008.  Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study.. The Prostate. 68(7):740-7. Abstract
B
Baker, SG, Darke AK, Pinsky P, Parnes HL, Kramer BS.  2010.  Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial.. Biostatistics (Oxford, England). 11(3):413-8. Abstract
C
Clark, JP, Munson KW, Gu JW, Lamparska-Kupsik K, Chan KG, Yoshida JS, Kawachi MH, Crocitto LE, Wilson TG, Feng Z et al..  2008.  Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.. Clinical chemistry. 54(12):2007-17. Abstract
D
Draisma, G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
E
Etzioni, R, Feuer E.  2008.  Studies of prostate-cancer mortality: caution advised.. The lancet oncology. 9(5):407-9.
Etzioni, R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Etzioni, R, Gulati R, Falcon S, Penson DF.  2008.  Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.. Medical decision making : an international journal of the Society for Medical Decision Making. 28(3):323-31. Abstract
G
Gonzalez, A, Peters U, Lampe JW, White E.  2009.  Zinc intake from supplements and diet and prostate cancer.. Nutrition and cancer. 61(2):206-15. Abstract
Gulati, R, Inoue L, Katcher J, Hazelton W, Etzioni R.  2010.  Calibrating disease progression models using population data: a critical precursor to policy development in cancer control.. Biostatistics (Oxford, England). 11(4):707-19. Abstract
H
Huang, Y, Isharwal S, Haese A, Chun FKH, Makarov DV, Feng Z, Han M, Humphreys E, Epstein JI, Partin AW et al..  2011.  Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.. BJU international. 107(10):1562-9. Abstract
Huang, Y, Pepe MS.  2009.  A parametric ROC model-based approach for evaluating the predictiveness of continuous markers in case-control studies.. Biometrics. 65(4):1133-44. Abstract
Huang, Y, Pepe MS.  2010.  Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods.. Statistics in medicine. 29(13):1391-410. Abstract
Hussain, M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
Hussain, M, Tangen CM, Berry DL, Higano CS, Crawford DE, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ et al..  2013.  Intermittent versus continuous androgen deprivation in prostate cancer.. The New England journal of medicine. 368(14):1314-25. Abstract
J
Janes, H, Pepe MS.  2008.  Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting.. American journal of epidemiology. 168(1):89-97. Abstract
K
Kristal, AR, Arnold KB, Neuhouser ML, Goodman P, Platz EA, Albanes D, Thompson IM.  2010.  Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial.. American journal of epidemiology. 172(5):566-77. Abstract
L
Lin, B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS et al..  2008.  WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(5):1397-406. Abstract
Lin, DW.  2009.  Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.. Urologic oncology. 27(3):315-21. Abstract
M
McLerran, D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J et al..  2008.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.. Clinical chemistry. 54(1):53-60. Abstract
Montgomery, BR, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS.  2008.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.. Cancer research. 68(11):4447-54. Abstract
Morgan, TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL.  2010.  Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen.. The Journal of urology. 184(6):2303-7. Abstract
Muus, KJ, Baker-Demaray T, McDonald LR, Ludtke RL, Allery AJ, Bogart AT, Goldberg J, Ramsey SD, Buchwald DS.  2009.  Body mass index and cancer screening in older American Indian and Alaska Native men.. The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association. 25(1):104-8. Abstract
N
Newcomb, LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW.  2010.  Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.. Urology. 75(2):407-13. Abstract
P
Page, ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS, Matsumoto AM.  2011.  Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.. The Journal of clinical endocrinology and metabolism. 96(2):430-7. Abstract
Pepe, MS, Feng Z, Huang Y, Longton G, Prentice RL, Thompson IM, Zheng Y.  2008.  Integrating the predictiveness of a marker with its performance as a classifier.. American journal of epidemiology. 167(3):362-8. Abstract